Sanifit to present at the 2018 European Biotech Investor Day in New York City


Palma, Spain and San Diego, USA, July 17, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, will present at the European Biotech Investor Day in NYC, organized by Solebury Trout, Goodwin LLC and Nasdaq.

Sanifit will present at 3.00 PM on Thursday, July 19. Dr Joan Perelló, CEO at Sanifit, will discuss the company’s clinical progress and financing plans for the continued development of SNF472 for the treatment of calciphylaxis and cardiovascular disease in patients suffering from end stage kidney disease and undergoing dialysis.

The European Biotech Investor Day in NYC, features privately-held and EU-listed biotechnology companies representing the “Next Wave of Opportunities” emerging from Europe. The life science – focused conference will be held at Goodwin LLC offices in the New York Times building.

For media enquiries:
Antonio Jiménez, VP Operations


About SNF472
SNF472 is an intravenous formulation of myo-inositol hexaphosphate with a novel mechanism of action for the treatment of haemodialysis patients with cardiovascular diseases linked to calcification. SNF472 is being developed for two indications: calciphylaxis and cardiovascular disease in end stage renal disease (CV-ESRD) patients undergoing dialysis. SNF472 has orphan drug status for the treatment of calciphylaxis from both the EMA and FDA. SNF472 selectively blocks the progression of pathological cardiovascular calcification, and poses an innovative solution for these unmet medical needs.

About Sanifit
Sanifit is a biopharmaceutical company focused on calcification disorders. The company was founded in 2007 as a spin-off of the University of the Balearic Islands and expanded its activities in the USA in 2016 with the incorporation of a subsidiary with offices in San Diego. The company’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, with a Phase 3 pivotal study planned to initiate in 2H 2018. The company is also investigating SNF472 in a Phase 2b study in CV-ESRD, with results expected in Q4 2019. Sanifit has raised more than $50M, including a series C funding of $41.3M (€36.6M) in mid-2015. For more information please visit

Press Release